2023-505791-30-01招募中3 期
A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy
Bcn Peptides S.A.10 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年10月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 10
- 主要终点
- Reduction or arrest of the microvascular impairment, based on the quantification of the number of microaneurysms in the central retinal field in patients with moderately severe to severe NPDR assessed by FA.
研究概览
简要总结
The main objective of RETISOM is to confirm the efficacy of COLIRIOBCN070660, administered twice daily for 1 year, in reducing or arresting the number of microaneurysms in patients with moderately severe to severe NPDR
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Men or women with ≥ 18 years old at the time of signing the informed consent.
- •Diagnosis of diabetes mellitus (type I or type II).
- •Moderately severe or severe NPDR (ETDRS levels 47 or 53) in the Study Eye as determined by the Central Reading Centre.
- •BCVA ETDRS letter score in the Study eye of ≥60 letters (approximate Snellen equivalent of 20/63 or better).
- •Willing and able to comply with clinic visits and study-related procedures.
- •Provide a signed informed consent.
排除标准
- •Presence of CI-DME or other pathologies involving edema in the study eye, confirmed by evaluation of OCT images measured by the Central Reading Center (CRC) according to the following thresholds for Zeiss Cirrus: - ≥ 290 μm in women - ≥ 305 μm in men
- •History of YAG capsulotomy in the study eye performed within the last 2 months prior to Screening.
- •History of DME or DR treatment with laser photocoagulation in the study eye or intraocular injections of steroids or anti-VEGF medication in any of the two eyes within the prior 12 months to Screening.
- •Active glaucoma treatment with prostaglandin analogues or carbonic anhydrase inhibitors. Alfa agonists and beta blockers are allowed.
- •Patients that change diabetes mellitus treatment (including initiation of insulin treatment) in the last 4 months, or plan to do so along the study.
- •HbA1C > 10.5 % at Screening.
- •Subject with a refractive error ≥ ± 5 diopter in the Study eye.
- •Inadequate ocular media, pupil dilatation or lack of cooperation to obtain CFP, FA and OCT images with sufficient quality.
- •Renal failure, dialysis or history of renal implant.
- •Uncontrolled blood pressure (defined as systolic > 180 mm Hg and/or diastolic > 110 mmHg while patient is sitting).
- •Somatostatin treatment, for any indication, in the previous 3 months from Screening.
- •Presence of retinal neovascularization in the study eye on clinical exam, by 7-field or ultra-widefield CFP.
- •Condition or situation which may put the subject at significant risk, may confound the study results or may interfere significantly with the patient’s participation in the study.
- •Pregnant or nursing or intending to become pregnant along the study.
- •Hypersensitivity to the active substance to be tested or to any of the excipients.
- •Known allergy to fluorescein dye.
- •Participation in an investigational study within 30 days prior to Screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
- •Current ASNV (Anterior Segment Neovascularization), vitreous haemorrhage, or tractional retinal detachment in the study eye.
- •Any ocular condition (other than DR) in the study eye that, in the opinion of the investigator, would prevent a visual acuity improvement (e.g., clinical signs of glaucoma, clinically relevant cataract).
- •Intraocular pressure (IOP) ≥ 22 mm Hg in the study eye.
- •Presence of clinical signs of glaucoma in the study eye.
- •Evidence of active inflammation or infection in either eye, including very frequent and chronic inflammations such as blepharitis and conjunctivitis.
- •History of aphakia in the study eye.
- •History of major ocular surgery in the study eye (cataract/glaucoma/retinal detachment surgery) within prior 6 months of Screening.
结局指标
主要结局
Reduction or arrest of the microvascular impairment, based on the quantification of the number of microaneurysms in the central retinal field in patients with moderately severe to severe NPDR assessed by FA.
Reduction or arrest of the microvascular impairment, based on the quantification of the number of microaneurysms in the central retinal field in patients with moderately severe to severe NPDR assessed by FA.
次要结局
- Change on number of haemorrhages (Hmas) in the central retinal field by FA.
- Change on the number of MAs and Hmas in the central field by CFP.
- Change on ETDRS severity level assessed by 7-field or ultra-widefield CFP.
- Changes on Retinal thickness assessed by OCT.
- Changes on Vessel density assessed by OCTA.
- Changes on Foveal Avascular Zone (FAZ) growth assessed by OCTA.
- Changes on visual acuity assessed (BCVA) using the 4-meter ETDRS protocol.
- Proportion of patients who change by ≥ 2 steps in the ETDRS severity scale.
- Proportion of patients who change on DR severity level assessed by 7-field or ultra-widefield CFP.
- Incidence and time to development of proliferative diabetic retinopathy (PDR) assessed by 7-field or ultra-widefield CFP.
- Incidence and time to development of Central-Involved Diabetic Macular Edema (CI-DME) assessed by OCT.
- Incidence and time to development of vision-threating complications due to DR (composite of PDR, CI-DME or anterior segment neovascularization (ASNV)) assessed by 7-field or ultra-widefield CFP, OCT, slit lamp examination or indirect ophthalmoscopy.
- Changes on DR biomarkers
研究者
CT Info Desk
Scientific
Bcn Peptides S.A.
研究点 (10)
Loading locations...
相似试验
尚未招募
3 期
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human ThrombopoietinCTIT-Chemotherapy Induced ThrombocytopeniaNCT06440824Shandong University60
已完成
2 期
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsMDSMyelodysplastic SyndromesThrombocytopeniaNCT00321711Amgen69
尚未招募
2 期
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic AnemiaAplastic AnemiaNCT07001254Anjali Sharathkumar15
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionNCT05797610Hoffmann-La Roche459
已完成
1 期
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsThrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraNCT00515203Amgen22